Thrombosis and recombinant factor VIIa
Author:
- 1 October 2004
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (10) , 1698-1699
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activityJournal of Thrombosis and Haemostasis, 2004
- Monitoring the bioavailability of FEIBA with a thrombin generation assayJournal of Thrombosis and Haemostasis, 2003
- Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation AssayPathophysiology of Haemostasis and Thrombosis, 2003
- Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBABlood Coagulation & Fibrinolysis, 2002
- Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse eventsHaemophilia, 2002
- Recombinant Factor VIIa Does not Induce Hypercoagulability In VitroThrombosis and Haemostasis, 1999
- Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX InhibitorsThrombosis and Haemostasis, 1997
- Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high- dose factor VIIa in hemophilia [see comments]Blood, 1994
- The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitorsBlood, 1983
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980